Evidence map›Paper›PMID 40832229›Full record

ArticlebioRxiv : the preprint server for biology2025

Mechanistic insights and

Naveen Kumar, Zonghui Ma, Fuquan Long, Srinivasa Reddy Bonam, Hsien-Tsung Lai, Shwu-Yuan Wu, Haiying Chen, Nicholas C Hazell, Jiani Bei, Xuefeng Liu and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Naveen KumarDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Zonghui MaChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Fuquan LongDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Srinivasa Reddy BonamDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Hsien-Tsung LaiSimmons Comprehensive Cancer Center, Department of Biochemistry, and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA 75390.
Shwu-Yuan WuSimmons Comprehensive Cancer Center, Department of Biochemistry, and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA 75390.
Haiying ChenChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Nicholas C HazellDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Jiani BeiDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Xuefeng LiuDepartment of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA 43210.
Zhi WeiDepartment of Computer Science, of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA 07102.
Cheng-Ming ChiangSimmons Comprehensive Cancer Center, Department of Biochemistry, and Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA 75390.
Jia ZhouChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA 77555.
Haitao HuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA 77555.ORCID 0000-0002-6964-2314

Funding

Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Modulation of BRD4 to epigenetically suppress HIVR01AI157852 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HU, HAITAO · 2021 to 2025
$3.0M
Opposing Functions of BRD4 Isoforms in Breast CancerR01CA251698 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHIANG, CHENG-MING · 2020 to 2024
$2.3M
Small Compound Inhibitors Targeting HPV Genome ReplicationR01CA288743 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHENG-MING CHIANG · 2025 to 2026
$1.3M
Modulation of BRD4 to epigenetically suppress HIVR56AI145666 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HU, HAITAO · 2019 to 2019
$554k
Development of a Pan-COVID-19 Vaccine CandidateR41AI181134 · NIAID · RNA THERAPEUTICS INC. · PI HU, HAITAO · 2024 to 2024
$300k
NCI NIH HHS R01 CA251698NCI NIH HHS R01 CA288743NIAID NIH HHS R01 AI157852NIAID NIH HHS R41 AI181134NIAID NIH HHS R56 AI145666NIAID NIH HHS T32 AI060549
6 · The paper itself

Abstract

Epigenetic suppression and durable silencing of HIV represent a promising strategy to achieve ART-free remission, consistent with the "block and lock" HIV cure paradigm. BRD4 is a host epigenetic reader and plays a critical role in HIV transcriptional regulation. We previously identified ZL0580, a first-in-class BRD4-selective small molecule distinct from the pan-BET inhibitor JQ1, which induces HIV epigenetic suppression. However, detailed molecular mechanisms, pharmacokinetics (PK), and

Indexed as

BRD4epigenetic suppressionHIVin vivo activityZL0580

Identifiers

PMID40832229
PMCPMC12363948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.